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1. Introduction 
Elevated intracranial pressure (ICP) is a frequently encountered problem in neurological 
and neurosurgical patients in the intensive care unit (ICU). It is most often seen in the 
setting of acute head trauma, however can also result from such causes as tumor, stroke, 
intracranial hemorrhage, or infection. Regardless of the cause, the degree and duration of 
ICP elevation has a direct and inverse relationship with morbidity and mortality. 
Consequently, despite the severity of the initial injury to the brain, a great deal of attention 
must often be focused on the monitoring and the management of ICP in acute neurological 
patients in the ICU setting.  
2. Physiology 
The brain is enclosed within inelastic container (the skull) or “closed box”, and the sum of 
volumes of intracranial contents is constant. The intracranial contents include blood, 
cerebrospinal fluid (CSF) and brain and an increase in the volume of one must be offset by a 
decrease in one or more of the other contents or an increase in ICP will result. Elevations in 
ICP are the result of an increase in cranial volume and a decrease in cranial compliance. This 
is best described by the Monro-Kellie hypothesis. (Figure 1) CSF is the most accommodating 
of the intracranial contents, however the compensatory capabilities of CSF are limited and 
once exhausted, small increases in intracranial volume result in large increases in ICP.  
The most common cause for raised ICP is severe head trauma. Regardless of etiology, the 
pathophysiology underlying the secondary injury from raised ICP is similar for all patients 
with brain injury and it results from such issues as swelling, edema, and neuronal 
cytotoxicity. Brain edema is a frequent occurrence in neurological diseases and can 
accumulate intracellular or extracellular. Intracellular edema is usully the result of cytotoxic 
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edema damaging the cell membranes often destroying the sodium/potassium exchange 
pump. This leads to unregulated passage of sodium and water into neuronal cells. 
Extracellular edema often results from capillary injuries at specific areas. This leads to 
breakdown of the blood brain barrier and leakage of protein and fluids into the extracellular 
space affected. A third category of edema, interstitial edema, is sometimes seen in acute 
obstructive hydrocephalus (See Table 1)  
 
Type of 
Edema 
Pattern Mechanism Differential 
Diagnosis 
Potential Therapies 
Vasogenic Extracellular 
spaces in white 
matter. 
Blood brain barrier 
breakbown 
secondary to 
capillary injury 
near focal lesions. 
Tumors. 
Hemorrhage. 
Infection. 
Inflammation. 
Surgery 
Antibiotics 
Steroid 
Hydrostatic Extracellular 
spaces in white 
matter and grey 
matter. Often 
diffuse. Can  
favor posterior 
circulation in 
PRES. Can be 
unilateral in 
CHS. 
Increased cerebral 
capillary water 
influx across blood 
brain barrier 
because of 
elevated pressure 
states. 
Hypertensive 
Emergencies. 
Hyperperfusion 
Syndromes. 
Hepatic 
Encephalopathy 
Antihypertensives 
 
Interstitial Prefers 
Periventricular 
white matter, 
especially 
frontal and 
occipital lobes. 
Transependymal 
flow of 
cerebrospinal fluid 
in hydrocephalus. 
Acute Obstructive 
Hydrocephalus. 
Shunt or EVD 
Cytotoxic Often 
intracellular. 
Prefers grey 
matter 
Na/K Pump 
breakdown and 
damaged cell 
membranes 
leading to water 
entry into cells and 
cellular swelling. 
Infarct. 
Trauma. 
Toxins. 
Hepatic 
Encephalopathy. 
Hypoxic Ischemic 
Encephalopathy 
Mannitol 
Hypertonic Saline 
Table 1. Types of Cerebral Edema 
When ICP remains severely and persistently elevated it is sometimes referred to as 
malignant intracranial hypertension and secondary brain injury is often the far more severe 
and deadly issue for the patient. ICP monitoring should be considered in any traumatic 
head injury presenting with a Glasgow coma score (GCS) of less than 9 and an abnormal 
computed tomography (CT) of head. Even in the absence of an abnormal CT scan, evidence 
suggests severe head trauma patients are still at significant risk of elevated ICP, particularly 
those greater than 40 years of age, showing signs of motor posturing, or having a systolic 
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blood pressure less 90 mmHg or less.1 A GCS of less than 9 and at least two of these three 
risk factors warrants consideration for continuous ICP monitoring, regardless of CT 
findings. ICP monitoring may also be warranted in cases where CSF flow appears disrupted 
or potentially disrupted. This is because of the potential for obstruction of drainage of flow 
of CSF and in the setting of acute brain injury, obstructive hydrocephalus can have an 
accelerating effect on ICP. This is often seen in the context of tumors, infections or 
hemorrhage either within the ventricular system or just outside of it. Whether the result of 
direct intraventricular obstruction or extraventricular mass effect with secondary ventricular 
system obstruction, these situations can lead to rapidly rising ICP and risk of deadly brain 
herniation.  
 
Fig. 1. ICP – Volume Curve showing exponential increases in ICP as skull compensatory 
mechanisms exhaust in the face of increasing intracranial volume. 
3. Monitoring 
Often by the time of clinical deterioration, ICP has been elevated for some time causing 
significant neuronal damage through progressive tissue swelling, ischemia, and 
hypoperfusion. Without emergent intervention, the process of deadly brain herniation may 
have already begun. Unfortunately, only the early stages are reversible and the clinical 
changes can be sudden. As a result, non-clinical modes of assessment such as continuous 
ICP monitoring have proven invaluable in head injury patients. Although there are several 
different forms of ICP monitoring devices, the external ventricular drain or catheter (EVD) 
has become the gold standard for accurate measurement and monitoring of ICP in the ICU. 
As its name implies, the EVD not only provides ICP monitoring, but allows for CSF 
drainage in response to ICP levels. Although associated with small risks of infection and 
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bleeding, the ability to recalibrate over time for sustained accuracy and the ability to drain 
CSF in response to ICP make the EVD superior to other ICP monitoring devices.  
The goal of ICP management is to prevent secondary brain injury, particularly from 
herniation or ischemia and infarction. Brain herniations occur as a result of pressure 
gradients created in the skull by either localized or generalized mass effect. Although, 
herniation is more likely to occur with progressive increases in ICP, there is no specific ICP 
known to be a threshold for herniation. Furthermore, certain herniations can occur without 
raised ICP, resulting solely from a localized pressure gradient such as in tentorial (uncal) 
herniation from a temporal lobe mass.2 Brain herniation is only reversible if treated early 
with aggressive medical and surgical intervention. Delays in treatment and inadequate 
treatment are associated with progressive herniation and severe and irreversible brain 
injury often leading to death. Special attention to the signs of brain herniation must be paid 
to all patients with raised ICP and to all patients with temporal lobe masses.  
Marked elevations in ICP lead to compromise in cerebral perfusion either locally or 
diffusely which in turn leads to ischemia and eventually infarction. CBF is closely correlated 
to cerebral perfusion pressure (CPP) through cerebral vascular resistance (CVR). Although, 
measures of CBF and CVR and not easily accessible, CPP can be calculated as the difference 
between mean arterial pressure (MAP) and ICP and CPP is often used as a surrogate for 
CBF. Although there is some conflicting evidence and opinion regarding the optimal CPP 
for head injury patients with raised ICP, the largest group of patients studied is within the 
traumatic brain injury population. It suggests that a CPP between 60 to 70 mmHg and ICP 
less than 20 mmHg may be associated with improved outcome and fewer complications 
from therapy in patients with brain injury and elevated ICP.3  
4. Managing ICP 
The medical management of ICP starts with principles of physiologic homeostasis including 
optimizing cerebral venous return. Evidence supports the practice of elevating the head of 
the bed to 30° or more for patients with raised ICP, however, in patients who are 
hypovolemic, this change in position may cause decreases in CPP by decreasing the MAP 
more than the ICP. Attention to CPP and ICP should be paid to ensure CPP is not 
compromised. Facilitating physiologic homeostasis also includes early treatment of factors 
that can worsen ICP such as fever, hypercarbia and seizures.  
Other medical management aimed at treating elevated ICP has been investigated for several 
years with limited success. Although several strategies have been shown to reduce ICP for 
short periods of time, very few have proven to be effective long term therapies or have a 
significant impact on patient outcome. One of the more commonly accepted approaches is to 
minimize agitation and excess muscle activity which can worsen ICP. This usually involves 
the use of analgesics and sedatives. The agents most commonly used are narcotics such as 
morphine and fentanyl for analgesics and benzodiazepines such as midazolam and 
lorazepam for sedation. In many cases, barbituates and anesthetics such as propofol, can be 
used in small or large doses in an attempt to decrease cerebral metabolism and cerebral 
oxygen requirements. This has been shown to reduce ICP and the decrease in cerebral 
oxygen requirements may result in a decrease in the absolute amount of cerebral blood flow 
needed to prevent further brain injury. The use of “drug induced coma” to decrease cerebral 
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metabolic rate remains controversial. This is largely because of the lack of convincing 
evidence that this approach changes outcome and the significant systemic and 
hemodynamic complications associated with these medications at high doses for long 
periods of time.5,6 Regardless, both barbituates and anesthetics such as propofol have been 
shown to be effective in decreasing ICP in a dose related fashion and assuming a patient is 
hemodynamically stable, these agents can often be used safely for extended periods with 
favorable responses on ICP. 
Occasionally, neuromuscular blockers are required, however routine use of neuromuscular 
blockers has not been shown to improve outcome and is associated with increased 
complications including pneumonia and sepsis. In the setting where paralysis is considered 
to control excess movements in association with persistently elevated ICP, encephalography 
(EEG) be considered to rule out ongoing seizures. Continuous EEG is used in some centres 
to monitor brain wave activity and to observe for the potential of non-clinical seizures. 
Although standard 20 minute EEG has not been shown to correlate with a high detection 
rate of seizures, any concern regarding the possibility of non-clinical seizures warrants 
assessment with EEG, if not continuous then intermittent.5 
Other medications focus on diuresing fluid, presumably edema, from the brain with osmotic 
diuretics or hypertonic solutions. The most extensively used agent is mannitol and various 
clinical and experimental studies have shown reductions in ICP with the use of mannitol.5 
The effect of mannitol on ICP involves several mechanisms including decreasing blood 
viscosity, decreasing CSF production, and fluid shift from brain tissue to intravascular 
compartments. The effects are usually not sustained and repeated doses over a prolonged 
period are often required. Earlier studies have also suggested the effects of mannitol on ICP 
could be prolonged with the concomitant use of furosomide. Whether used alone or in 
combination with another diuretic, prolonged mannitol use can lead to problems with 
dehydration, elevated serum osmolality, and renal impairment. Furthermore, the use of 
mannitol is less effective and potentially aggravating in cases of localized lesions with 
significant vasogenic edema, such as hemispheric ischemic strokes. In such cases, localized 
pressure gradient or a compartmentalized ICP is a more likely cause of neurological 
deterioration rather than a generalized increase in ICP.7 The effects of mannitol in these 
cases will be seen maximally in normal and non affected areas of the brain which can 
potential worsen the pressure gradient further.8 Kauffman et al investigated mannitol in the 
treatment of vasogenic cerebral edema following ischemic stroke and found that with 
multiple mannitol injections, non-infarcted hemisphere shrunk more compared to the 
infarcted hemisphere. He concluded that prolonged mannitol use may actually cause a 
reversal of the osmotic gradient between edematous brain and plasma, and worsen localized 
vasogenic edema in cases of large ischemic strokes with vasogenic edema.9 Similarly, several 
stroke specific trials found that if hyperosmolar therapy was used continuously for greater 
than 48 hours, it was associated with worse outcome and increased risk of herniation. The 
effects are felt to be secondary to increasing ICP differentials between infarcted brain and 
healthy brain and thereby increasing the chances of herniation, as the osmotic agents may 
collect in the infarcted tissue and then induce increasing edema. Consequently, mannitol 
                                                 
5 Scozzafava J, Hussain MS, Brindley PG, Jacka MJ, Gross D. The role of 20 minute EEG in the comatose 
patient. Journal of Clinical Neurosciences. Jan 2010;17(1):64-8. 
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should be used cautiously in any patient with hemispheric masses or lesions and in cases 
where repeated dose are to be used for a prolonged period of time. In more recent years, 
hypertonic saline has also been used and like mannitol, hypertonic saline acts by pulling 
water from brain tissue to the intravascular space. Hypertonic saline is associated with 
slightly less concerns regarding electrolyte disturbance, dehydration and renal injury, 
however similar precautions should be taken in regards to hemispheric lesions, particularly 
ischemic strokes with significant vasogenic edema. At the present time, there are no 
established guidelines for its use, however most studies have used 3% or 7.5% at rates of 20 
to 40 cc/hr. Prolonged infusions should be run only in an ICU setting and discontinuation 
should be tapered slowly to prevent rebound hyponatremia. 
Several other measures should be considered second tier in the management of ICP because 
of their lack of proven benefit and/or the significant risks associated with their use. These 
include hyperventilation and hypothermia. For years, hyperventilation was thought to be a 
safe and effective method of lowering ICP. Its action is through generalized vasoconstriction 
of small cerebral arteries in response to low carbon dioxide levels in the blood. It causes a 
relatively quick decrease in ICP at the expense of a corresponding decrease in CBF and at 
the risk of resultant cerebral ischemia. Further evidence has shown hyperventilation to be an 
ineffective method of managing ICP and possibly detrimental in several subgroups of 
patients.13 Its use should be avoided in most circumstances. 
The concept of hypothermia as a possible neuroprotectant has been explored for several 
years. Evidence exists that induced hypothermia lowers ICP, likely through decreasing 
cerebral metabolic rate, however it has not been shown to correlate to a decreased rate of 
secondary brain injury. Although increasing evidence suggests a role for therapeutic 
hypothermia to protect the brain from secondary injury following cardiac arrest, similar 
evidence has not developed in other situations, particularly primary brain injury such as 
trauma and stroke. A randomized controlled trial in severe closed head injury failed to show 
any benefit of induced hypothermia on outcome.14 Further trials in various subgroups of 
patients are underway. 
In many cases, ICP proves resistant to aggressive medical management and surgical 
intervention is required beyond the EVD. This is frequently seen in association with mass 
lesions. Mass lesions can include tumors, abscesses or hemorrhages which are all frequently 
prone to edema which further aggravates ICP and poses an increasing risk of herniation. In 
the case of tumors, resection often results in resolution of ICP issues. In the case of abscess, 
drainage not only serves to reduce ICP, but treats the infection and prevents further spread.  
The recommended management of hematoma depends on location, size of hematoma and 
extent of neurological injury as well as ICP. Subdural and epidural hematomas causing 
increased ICP generally should be considered for surgical evacuation. Subarachnoid 
hemorrhage (SAH) is often the result of a ruptured cerebral artery aneurysm or 
arteriovenous malformation. Definitive management of the hemorrhage and the ICP must 
involve securing the ruptured vessel(s). In cases of parenchymal intracerebral hemorrhage 
(ICH) or hemorrhagic stroke, several randomized trials have failed to demonstrate benefit 
associated with surgical evacuation of supratentorial ICH, regardless of ICP.15  
However, there is one sub-group of hemorrhagic stroke that has shown to benefit from 
aggressive and early surgical intervention. Although, there are no randomized trials looking 
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specifically at surgical evacuation of cerebellar hematomas, a non-randomized case series 
has shown urgent surgical evacuation of cerebellar hemorrhage improves outcome 
compared to medical management alone.16 It included patients with GCS < 13, and 
hematoma > 40 mm. 45 patients were treated medically and 30 patients were treated with 
decompressive surgery. Good outcome occurred 58% with surgery while only 18% with 
conservative medical therapy. A large reason for this may be because of the reasonable 
potential for recovery regardless of stroke burden in cerebellum. The factor which is often 
more critical is the acute and progressing edema and/or hemorrhage which may prove to 
compromise the nearby fourth ventricle of the ventricular system and lead to obstructive 
hydrocephalus. As a result, a cerebellar hemorrhage which would otherwise have 
potentially good outcome, could rapidly progress to malignant intracranial hypertension 
and death. Our recommendation is for the prophylactic insertion of EVD or suboccipital 
decompressive craniectomy for patients with cerebellar hemorrhage and hematoma > 3 cm 
in diameter or obstructive hydrocephalus.  
Medically intractable ICP is also frequently seen with severe head trauma. Unlike mass 
lesions and vascular anomalies, an underlying structural abnormality cannot be removed 
unless associated with significant secondary hematoma. Surgical treatment of ICP has 
focused on brain decompression in these patients. Both hemispheric and bifrontal 
craniectomy have both been shown to be effective in managing medically intractable ICP 
following head trauma and should be considered when medical measures have failed.17-22 
Decompressive craniectomy for prevention of fatal brain herniation has been for almost 100 
years. The rationale for surgery is to change the inelastic container or ‘closed box’ and 
provide a mechanical outlet for the edematous brain to stretch beyond the skull thereby 
preventing herniation. As a consequence, secondary benefits include rapid reduction of 
intractable ICP and restoration of cerebral perfusion.  
5. Considerations specific to ischemic stroke 
Issues regarding raised ICP are less often encountered in ischemic stroke compared to 
hemorrhagic stroke. Similarly, the management of malignant intracranial hypertension is far 
less seen is ischemic stroke patients compared to hemorrhagic stroke or other neurology and 
neurosurgery patients presenting with mass lesions. This is because in the case of ischemic 
stroke, a new mass or volume is not immediately introduced into our “closed box” model of 
intracranial contents like with other causes of brain injury like hemorrhage or tumor. However, 
immediately after the onset of ischemia changes begin to occur including cerebral edema. 
It has been estimated that anywhere from 1-10% of supratentorial ischemic strokes can cause 
rapid neurological deterioration from space-occupying cerebral edema. Although ischemic 
strokes display some vasogenic edema as part of the inflammatory phase, the primary 
swelling is the result of cytotoxic edema. Cytotoxic edema is the result of damaged cell 
membranes during ischemia. The result is that neuronal cells fill with plasma ultrafiltrate. 
Although this usually occurs between the second and fifth day after stroke, it can occur as 
early as 24 hours. Such a presentation following an ischemic stroke involving the entire 
middle cerebral artery (MCA) territory is called ‘malignant MCA infarction’ (MMI). This is 
often a consequence of occlusion of the internal carotid artery or the proximal portion of the 
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middle cerebral artery. The prognosis of MMI is poor and mortality is as high as 80%, with 
most deaths occurring during the first week from cerebral edema and brain herniation.23  
Multiple non-randomized studies have shown that decompressive surgery, consisting of a 
hemicraniectomy and duraplasty reduces mortality in patients with MMI.24-26 However, its 
popularity decreased because clinicians were concerned as to whether survival was at the 
expense of poor functional outcome. In the midst of uncertainty regarding functional 
outcome, three European trials have addressed the role of decompressive hemicraniectomy 
on functional outcome since 2000: the French DECIMAL (decompressive craniectomy in 
malignant middle cerebral artery infarcts) trial; the German DESTINY (decompressive 
surgery for the treatment of malignant infarction of the middle cerebral artery) trial; and the 
Dutch HAMLET trial (hemicraniectomy after middle cerebral artery infarction with life-
threatening edema trial). A pooled analysis of all three trials confirmed suggestions from 
earlier non-randomized trials. Decompressive hemicraniectomy undertaken within 48 hours 
of onset of MMI reduces mortality and increases the number of patients with a favorable 
functional outcome.27-30  
The trials were both praised and criticized on many points. Analysis of all the trials was 
assumed possible due to similar design and use of the modified Rankin Scale (mRS) as a 
common primary outcome measure. Significant difference between the trials included 
imaging modalities and longer treatment window allowed in HAMLET, which allowed 
patients to be treated up to 96 hours after onset of stroke symptoms. However, the pooled 
analysis included only the patients randomized and treated within 48 hours. The primary 
outcome measure for the pooled analysis was the mRS dichotomized between “favorable” 
(defined as mRS 0-4) and “unfavorable” (mRS 5-6). There was clearly a difference between 
the two treatment arms, with 75% achieving a favorable outcome in the hemicraniectomy 
group as compared to 24% in the medical treatment alone arm (p< 0.01). The most robust 
effect was seen on survival, which increased from 28% to nearly 80% with DCH. Perhaps the 
most significant result was the proportion of patients who were independent with disability 
(mRS 2) which increased more than five times with DCH from 2.5% to 14%. Forty three 
percent of patients had a good clinical outcome with mRS 2-3 after a DCH compared to 
21.5% of patients who received conservative therapy. However, the proportion of patients 
surviving with moderate-to-severe disability was increased more than 12-fold (31% vs. 
2.5%) but the rates of very severe disability was not increased after DCH (4%vs. 5%).  
Despite the evidence provided by these trials, the most crucial question remains the selection 
of patients for surgery because not all middle cerebral infarctions lead to MMI and no single 
prognostic factor has been identified as a predictor of fatal outcome in MMI. Neuroimaging 
combined with clinical examination does provide valuable information to identify patients at 
risk. Early ischemic changes (less than 6 hours) on CT scan that involves greater than 50% of 
the MCA territory have been associated with fatal outcomes. This included such early CT 
changes as localized cerebral edema causing sulcal effacement or compression of the lateral 
ventricle.31 The DECIMAL trial used a critical stroke volume of 145 mL on diffusion-weighted 
MRI and confirmed this cut off value suggested by previous authors. Analysis showed 78% 
mortality in strokes with >145 mL volume and no deaths when the stroke volume was less 
than 145mL. NIHSS > 20 (dominant hemisphere) or > 15 (non-dominant hemisphere) within 6 
hours of symptom onset along with CT findings of hypodensity >50% were also associated 
with high risk for developing malignant cerebral edema. 32  
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Age is another important consideration in this population following MMI. The upper age 
limit in the above randomized trials was 60-years and therefore the results are not easily 
transferable to individuals older than 60 years. As we have seen with many interventions, 
with older patient populations come more medically complex and often fragile patients. 
DESTINY II is underway to evaluate the benefit of surgery in this older patient population, 
which may be more indicative of the stroke population seen in most hospitals. However, 
non-randomized trials which investigated this question showed that mortality and poor 
outcome were significantly higher in patients older than 60 years of age.33,34 Regardless of 
the results of DESTINY II, the decision to operate on patients older than 60 years of age 
should be individualized and must take into consideration patients declared wishes and 
social support. It must be kept in mind that outcomes in this population depend on several 
factors like admission functional status, cognitive ability and presence of social support. 
The timing of surgery is also significant. From the individual results and pooled analysis of 
DECIMAL and DESTINY, patients who were surgically treated with decompressive 
hemicraniectomy within 48 hours did better when compared to the HAMLET trial in which 
there was no improvement in functional outcome despite decrease in mortality in patients 
who received delayed surgical treatment (up to 96 hours after symptoms onset). Early 
decompressive hemicraniectomy (<48hours) is recommended for all patients with MMI and 
impending herniation who are felt to have good potential for recovery from the initial 
ischemic injury of the stroke.  
In contrast to supratentorial ischemic strokes, the question of surgical intervention in large 
cerebellar strokes is less controversial. Fatal space occupying edema can develop in 17% -
54% of cerebellar strokes resulting in obstructive hydrocephalus, transforaminal or 
transtentorial herniation and brain stem compression. Although lacking evidence from 
randomized clinical trials, it is widely accepted that surgical intervention with suboccipital 
decompressive craniectomy or insertion of an external ventricular drainage is lifesaving in 
malignant cerebellar infarctions and with the potential for good clinical outcomes. The long 
term outcome in survivors is also good, especially where there is no associated brainstem 
infarction.35,36 Similar to cerebellar hematoma, these patients should be considered for early 
decompression.  
6. ICP in aneurysmal subarachnoid hemorrhage 
Case report and case series evidence in aneurysmal SAH continues to emerge describing 
beneficial effects of decompressive craniectomy on elevated ICP and on outcome. The 
factors affecting ICP in aneurysmal SAH can include ongoing hemorrhage, edema and 
vasospasm with secondary ischemia. In cases of high grade SAH with severely and 
persistently elevated ICP, decompressive craniectomy should be considered in conjunction 
with early securing of aneurysm in an effort to maximize the chances of good outcome.37,38 
Location of SAH may also play a factor in both outcome and surgical approach. Case series 
evidence has described dramatic recoveries in patients with high grade SAH from anterior 
communicating artery aneurysm ruptures and malignant ICP managed with bifrontal 
decompressive craniectomy.39 The evidence may be related to the observation that high 
grade SAH from anterior communicating artery aneurysm ruptures often present without 
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significant initial brain tissue injury but with significant subarachnoid hematoma and 
dramatic bilateral cerebral edema. The prominent edema associated with these SAH’s often 
precipitates uncontrollable ICP levels and surgical management of the ICP with craniectomy 
may offer the opportunity for hematoma resolution and often dramatic recovery. A 
randomized controlled trial has been initiated to investigate this further. 
7. Conclusion 
The management of ICP is critical in patients with brain injury, whether from trauma, stroke 
or hemorrhage. Although recovery is inevitably limited by the degree of initial injury 
incurred, morbidity and mortality rise dramatically in the face of uncontrollable ICP. The 
management of elevated ICP has evolved significantly over the past century. Despite 
extensive research for many years, evidence for most medical therapies is lacking. In recent 
years, redirection toward early surgical intervention has re-emerged, particularly with 
subsets of trauma, stroke and subarachnoid hemorrhage patients. Evidence from case 
reports and small trials will need to be supported by larger trials. Even evidence from large 
trials needs to be scrutinized and challenged again with further trials to determine which 
patients may benefit the most from which therapies, particularly decompressive surgery. 
This may lead to more focused and more successful management of all patients with ICP 
issues. Inevitably all therapies have to be individualized to each individual case. In the mean 
time, courage and determination are needed by healthcare providers dealing with these 
emergencies since delays in recognition and intervention are often fatal. 
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